Immunity to influenza: The challenges of protecting an aging population

Immunologic Research

Volumn 29, Issue 1-3, 2004, Pages 113-124

  Katz, Jacqueline M ^a   Plowden, Julie ^a   Renshaw Hoelscher, Mary ^a   Lu, Xiuhua ^a   Tumpey, Terrence M ^a   Sambhara, Suryaprakash ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

Aging; Immune response; Influenza virus; Pandemics

Indexed keywords

CELL ADHESION MOLECULE; CRL 1005; DNA VACCINE; DOUBLE STRANDED RNA; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; ISCOM; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG;

ACUTE RESPIRATORY TRACT DISEASE; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; CELL ACTIVATION; CELLULAR IMMUNITY; CONJUNCTIVITIS; CYTOKINE PRODUCTION; DISEASE RESISTANCE; DRUG DELIVERY SYSTEM; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNOMODULATION; INFLUENZA; INFLUENZA VIRUS; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR RECOGNITION; MORBIDITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW;

ADJUVANTS, IMMUNOLOGIC; AGED; AGING; ANIMALS; DISEASE OUTBREAKS; HUMANS; IMMUNITY, ACTIVE; IMMUNITY, NATURAL; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MEMBRANE GLYCOPROTEINS; MICE; ORTHOMYXOVIRIDAE; POLYMERS; RECEPTORS, CELL SURFACE; TOLL-LIKE RECEPTORS;

EID: 3042615586     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1385/IR:29:1-3:113     Document Type: Review

References (51)

1. Simonsen L, Fukuda K, Schonberger LB, Cox NJ: Impact of influenza epidemics on hospitalizations. J Infect Dis 2000;181:831-837.
2. Simonsen L, Clarke MJ, Williamson GD, Stroup DF, Arden NH, Achonberger LB: Impact of influenza epidemics on mortality: introduction of a severity index. Am J Public Health 1997;87:1944-1950.
3. Thompson WW, Shay DK, Weintraub A, Brammer L, Cox NJ, Anderson LJ, Fukuda K: Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003;289:179-186.
4. Centers for Disease Control and Prevention, National Center for Health Statistics, Health United States 1998; US Department of Health and Human Services, CDC, 1998; DHHS publication no. (PHS) 98-1232.
5. Centers for Disease Control and Prevention. Prevention and Control of Influenza-recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbid Mortal Wkly 2003;52:1-35.
6. Patriarca PA, Weber JA, Parker RA, et al.: Efficacy of influenza vaccine in nursing homes reduction in illness and complications during an influenza A (H3N2) epidemic. JAMA 1985;253:1136-1139.
7. Monto AS, Hornbuckle K, Ohmit SE: Influenza vaccine effectiveness among elderly nursing home residents: a cohort study. Am J Epidemiol 2001;154:15-60.
8. Wright PF, Webster RG: Orthomyxoviruses. In Field's Virology, 4th ed. Knipe DM, Howley PM, eds. Lippincott-Raven, Philadelphia, 2001, pp. 1533-1579.
9. Subbarao K, Katz JM: Avian influenza viruses infecting humans. Cell Mol Life Sci 2000;57:1770-1784.
10. Centers for Disease Control and Prevention: Update: influenza activity: United States and Worldwide, 2002-03 season and composition of the 2003-04 influenza vaccine. Morbid Mortal Wkly 2003;52:516-521.
11. Treanor JJ, Wilkinson BE, Masseoud F, Hu-Primmer J, Battaglia R, O'Brien D, et al.: Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 2001;19:1732-1737.
12. Nicholson KG, Colegate AE, Podda A, Stephenson I, Wood J, Ypma E, Zambon MC: Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomized trial of two potential vaccines against H5N1 influenza. Lancet 2001;357:1937-1943.
13. Simonsen L, Clarke MJ, Schonberger LB, Arden NH, Cox NJ, Fukuda K: Pandemic versus epidemic influenza mortality: a pattern of changing age distribution. J Infect Dis 1998;178:53-60.
14. Nicholson KG, Kent J, Hammersley V, Cancio E: Acute viral infections of upper respiratory tract in elderly people living in the community: comparative, prospective, population based study of disease burden. Br Med J 1997;315:1060.
15. Crossley KB, Peterson PK. Infections in the elderly. In Principles and Practice of Infectious Diseases, 5th ed. Mandell GL, Bennett JE, Dolin R, eds. Churchill Livingstone, Philadelphia, 2000, pp. 3164-3169.
16. Meyer KC: The role of immunity in susceptibility to respiratory infection in the aging lung. Respir Physiol 2001;128:23.
17. Ginaldi L, Loreto MF, Corsi MP, Modesti M, De Martinis M: Immunosenescence and infectious diseases. Microbes Infect 2001;3:851-857.
18. Miller RA: The aging immune system: primer and prospectus. Science 1996;273:70-74.
19. Claeys S, de Belder T, Holtappels G, Gevaert P, Verhasselt B, van Cauwenberge P, Bachert C: Human beta-defensins and toll-like receptors in the upper airway. Allergy 2003;58:748-753.
20. Hoffman, JA, Kafatos FC, Janeway CA, Ezekowitz RA: Phylogenetic perspectives in innate immunity. Science 1999;284:1313-1318.
21. Akira S, Takeda K, Kaisho T: Toll-like receptors:critical proteins linking innate and adaptive immunity. Nature Immunol 2001;2:675-680.
22. Alexopoulou LA, Holt C, Medzhitov R, Flavell RA: Recognition of double-stranded RNA and activation of NF-κB by toll-like receptor 3. Nature 2001;413:732-738.
23. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, et al.: Small anti-viral compunds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nature Immunol 2002;3:196-200.
24. Renshaw M, Rockwell J, Engleman C, Gewirtz A, Katz J, Sambhara S: Impaired Toll-like receptor expression and function in aging. J Immunol 2002;169:4697-4701.
25. Pawelec G, Barnett Y, Forsey R, Frasca D, Globerson A, McLeod J, et al.: T cells and aging, January 2002 update. Front. Biosci 2002;7:56-183.
26. Effros RB, Cai Z, Linton PJ: CD8 T cells and aging. Crit Rev Immunol 2003;23:61-80.
27. Sambhara S, Kurichh A, Miranda R, James O, Underdown B, Klein M, et al.: Severe impairment of primary but not memory responses to influenza viral antigens in aged mice. Co-stimulation in vivo partially reverses impaired primary immune responses. Cellular Immunol 2001;210:1-4.
28. Grubeck-Loebenstein B: Changes in the aging immune system. Biologicals 1997;25:205-208.
29. Effros RB, Walford RL: The effect of age on the antigen-presenting mechanism in limiting dilution precursor cell frequency analysis. Cell Immunol 1994;88:53-539.
30. Davenport FM, Hennessy AV, Askin FB: Lack of adjuvant effect of AIPO4 on purified influenza hemagglutinin in man. J Immunol 1968;100:1139-1140.
31. Minutello M, Senatore F, Cecchinelli G, Bianchi M, Andreani T, Podda A, Crovari P: Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine 1999;17:99-104.
32. De Donato S, Granoff D, Minutello M, Lecchi G, Faccini M, Agnello M, et al.: Safety and immunogenicity of MF-59-adjuvanted influenza vaccine in the elderly. Vaccine 1999;17:3094-3101.
33. Katz JM, Lu X, Todd CW, Newman MJ: A nonionic block co-polymer adjuvant (CRL1005) enhances the immunogenicity and efficacy of inactivated influenza vaccine in young and aged mice. Vaccine 2000;18:2177-2187.
34. de Jong JC, Claas EC, Osterhaus AD, Webster RG, Lim WL: A pandemic warning? Nature 1997;389:554.
35. Claas EC, Osterhaus AD, van Beek R, deJong JC, Rimmelzwaan GF, Senne DA, et al.: Human influenza H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 1998;351:472-477.
36. Subbarao K, Klimov A, Katz J, Regnery H, Lim W, Hall H, et al.: Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 1998;279:393-396.
37. Guo YJ, Li JW, Cheng I, Wang M, Zhou Y, Li XH, et al.: Discovery of humans infected by avian influenza A (H9N2) virus. Chinese J Exp Clin Virol 1999;15:105-108.
38. Lin YP, Shaw M, Gregory V, Cameron K, Lim W, Klimov A, et al.: Avian-to-human-transmission of H9N2 subtype influenza A viruses: Relationship between H9N2 and H5N1 human isolates. Proc Natl Acad Sci USA 2000;97:9654-6548.
39. Gao P, Watanabe S, Ito T, Goto H, Wells K, McGregor M, et al.: Biological heterogeneity, including systemic replication in mice, of H5N1 influenza A virus isolates from humans in Hong Kong. J Virol 1999;73:3184-3189.
40. Lu X, Tumpey TM, Morken T, Zaki SR, Cox NJ, Katz JM: A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans. J Virol 1999;73:5903-5911.
41. Tumpey TM, Lu X, Morken T, Zaki SR, Katz JM: Depletion of lymphocytes and diminished cytokine production in mice infected with a highly virulent influenza A (H5N1) virus isolated from humans. J Virol 2000;74:6105-6116.
42. Cheung CY, Poon LLM, Lau AS, Luk W, Lau YL, Shortridge KF, et al.: Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet 2002;360:1831-1837.
43. Seo, SH, Hoffmann E, Webster RG: Lethal H5N1 influenza viruses escape host anti-viral cytokine responses. Nat Med 2002;8:950-954.
44. Zitzow LA, Rowe T, Morken T, Shieh W-J, Zaki S, Katz JM: Pathogenesis of avian influenza A (H5N1) viruses in ferrets. J Virol 2002;76:4420-4429.
45. Gerdil C: The annual production cycle for influenza vaccine. Vaccine 2003;21:1776-1779.
46. Schulman JL, Kilbourne ED: Induction of partial specific heterotypic immunity in mice by a single infection with influenza A virus. J Bacteriol 1965;89:170-177.
47. Liang S, Mozdzanowska K, Pallandino G, Gerhard W: Heterosubtypic immunity to influenza type A virus in mice. J Immunol 1994;152:1653-1661.
48. Sonoguchi T, Naito H, Hara M, Takeuchi Y, Fukumi H: Cross-subtype protection in humans during sequential overlapping and/or concurrent epidemics caused by H3N2 and H1N1 virus infections. J Infect Dis 1985;151:81-88.
49. Sambhara S, Kurichh A, Miranda R, Tumpey T, Rowe T, Renshaw M, et al.: Heterosubtypic immunity against human Influenza A viruses including recently emerged avian H5 and H9 viruses induced by Flu-ISCOM vaccine in mice requires both CTL and macrophage function. Cell Immunol 2001;211:143-153.
50. Tumpey T, Renshaw M, Clements JD, Katz JM: Mucosal delivery of inactivated influenza vaccine induces B cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J Virol 2001;75:5141-5150.
51. Epstein SL, Tumpey TM, Misplon JA, Lo CY, Cooper LA, Subbarao K, et al.: DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerg Infect Dis 2002;8:796-801.